Investment Column: Alliance is not so great for missing rally

Alliance

Our view: Sell

Share price: 309. p (+0.5p)

Alliance Trust's chief executive, Katherine Garrett-Cox, has been saddled with one of those media nicknames that can so easily become a millstone. And that is exactly what "Katherine the Great" has become, given that the performance of Alliance Trust, the gigantic investment trust that she runs, has been anything but.

It was hard to find much to be positive about from yesterday's interim results. The trust was in the bottom quartile of its sector (Global Growth and Global Growth and Income Investment Trusts), having missed out on the stock market's summer rally.

Alliance says that it believes that "in some cases" there has been no fundamental change to the companies whose share prices have soared as a result of the rally. Its argument is that the increase in prices is not "necessarily reflective of any improvement in their underlying value". In other words, the market has got it wrong. That's a brave call for a company like Alliance to make, because if the companies behind the rally – financials, miners, cyclical stocks – retain their value and build on recent gains, Alliance will look rather silly.

Focusing on well-managed companies with healthy balance sheets and good cash flow is a great idea. But you have to pick the right ones as an active manager, otherwise your investors may as well invest in trackers. And tracking the FTSE All World index would have yielded a far better return than Alliance over the past six months. The Trust looks better over the year, but the 15 per cent discount to net asset value in the shares tells its own story. Of course, there is always a prospect of corporate action that could narrow this, but big generalist trusts tend to be difficult to shake up.

Alliance's long-term strategy looks sensible enough, the US and the UK are being focused on for income while Asia is there for growth, but it is not currently producing results, and the discount looms large. Great it may be in the future, but for the present, sell.



Morse

Our view: Hold

Share price: 34.65p (-0.35p)

Morse's woeful performance on the market over the past 18 months is hardly a mystery worthy of the eponymous television detective. The IT company has been battered by the onset of the downturn and falling demand. The stock was at 37.75p when this column last ran the slide rule over it a year ago. We said sell, and it subsequently plumbed the depths to about 4p, before climbing back up again.

Some felt Morse – which resells technology from companies including HP and IBM, as well as providing maintenance and support and business applications – had overstretched. However, it has since been streamlined, and the rocky finances are stabilised.

Morse has overhauled its board, bringing in chairman Kevin Loosemore and chief executive Mike Phillips to start the firefighting and turn the company around. The management also launched a restructuring plan which is now largely completed, and are looking towards growth in 2010.

Morse's annual results earlier this month showed a "very challenging" first nine months, according to Investec, but profits did rise in the fourth quarter. However, whether the server support and maintenance market – its biggest business – will return enough to make it worth a punt is debatable, especially as no dividend is expected until 2012.

Panmure has Morse on a price-to-earnings ratio of 6.6 times forecast full-year earnings, which doesn't look too demanding. But despite the positive end to the year – traditionally the group's strongest quarter – the upside isn't clear enough to pile in yet. The shares aren't likely to sink much either, though, so we feel that we can upgrade our view to a hold.



Allergy Therapeutics

Our view: Buy

Share price: 18.54p (+1.29p)

Despite green shoots now forming part of the everyday lexicon for small-cap biotechnology companies, equity funding is still hard to come by. That is why investors should pay special attention to Allergy Therapeutics, the Aim-listed vaccines group.

The company got a big vote of confidence from the markets, was able to cut much of its debt and restructure its balance sheet after raising £22m in a rights issue earlier this year. Yesterday's preliminary results were also encouraging: research and development spend has fallen from £16.3m to £5.3m after two trials came to an end, leading to a 20 per cent hike in gross profits and a reduced operating loss.

Investors in the biotech industry need share prices to rise (you've more chance of winning the lottery than getting a dividend), and those that bought these shares a year ago have seen their investment jump by 27.8 per cent.

The stock reflects the flow of good news, and while we remain bullish, we caution that the gains made over the last 12 months may not be quite as impressive going forward. Sill, buy.

News
peopleFrankie Boyle responds to referendum result in characteristically offensive style
Sport
Harry Redknapp. Mark Hughes and Ryan Shawcross
footballNews and updates as Queens Park Rangers host the Potters
Arts and Entertainment
tvHighs and lows of the cast's careers since 2004
News
news
PROMOTED VIDEO
New Articles
i100
Life and Style
Couples have been having sex less in 2014, according to a new survey
life
Arts and Entertainment
'New Tricks' star Dennis Waterman is departing from the show after he completes filming on two more episodes
tvHe is only remaining member of original cast
News
ebooksAn unforgettable anthology of contemporary reportage
New Articles
i100... with this review
Voices
Holly's review of Peterborough's Pizza Express quickly went viral on social media
New Articles
i100
Arts and Entertainment
musicHow female vocalists are now writing their own hits
Arts and Entertainment
musicBiographer Hunter Davies has collected nearly a hundred original manuscripts
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Senior BA - Motor and Home Insurance

£400 - £450 Per Day: Clearwater People Solutions Ltd: **URGENT CONTRACT ROLE**...

Market Risk & Control Manager

Up to £100k or £450p/d: Saxton Leigh: My client is a leading commodities tradi...

SQL Developer - Watford/NW London - £320 - £330 p/d - 6 months

£320 - £330 per day: Ashdown Group: The Ashdown Group have been engaged by a l...

Head of Audit

To £75,000 + Pension + Benefits + Bonus: Saxton Leigh: My client is looking f...

Day In a Page

Scottish referendum: The Yes vote was the love that dared speak its name, but it was not to be

Despite the result, this is the end of the status quo

Boyd Tonkin on the fall-out from the Scottish referendum
Manolo Blahnik: The high priest of heels talks flats, Englishness, and why he loves Mary Beard

Manolo Blahnik: Flats, Englishness, and Mary Beard

The shoe designer who has been dubbed 'the patron saint of the stiletto'
The Beatles biographer reveals exclusive original manuscripts of some of the best pop songs ever written

Scrambled eggs and LSD

Behind The Beatles' lyrics - thanks to Hunter Davis's original manuscript copies
'Normcore' fashion: Blending in is the new standing out in latest catwalk non-trend

'Normcore': Blending in is the new standing out

Just when fashion was in grave danger of running out of trends, it only went and invented the non-trend. Rebecca Gonsalves investigates
Dance’s new leading ladies fight back: How female vocalists are now writing their own hits

New leading ladies of dance fight back

How female vocalists are now writing their own hits
Mystery of the Ground Zero wedding photo

A shot in the dark

Mystery of the wedding photo from Ground Zero
His life, the universe and everything

His life, the universe and everything

New biography sheds light on comic genius of Douglas Adams
Save us from small screen superheroes

Save us from small screen superheroes

Shows like Agents of S.H.I.E.L.D are little more than marketing tools
Reach for the skies

Reach for the skies

From pools to football pitches, rooftop living is looking up
These are the 12 best hotel spas in the UK

12 best hotel spas in the UK

Some hotels go all out on facilities; others stand out for the sheer quality of treatments
These Iranian-controlled Shia militias used to specialise in killing American soldiers. Now they are fighting Isis, backed up by US airstrikes

Widespread fear of Isis is producing strange bedfellows

Iranian-controlled Shia militias that used to kill American soldiers are now fighting Isis, helped by US airstrikes
Topshop goes part Athena poster, part last spring Prada

Topshop goes part Athena poster, part last spring Prada

Shoppers don't come to Topshop for the unique
How to make a Lego masterpiece

How to make a Lego masterpiece

Toy breaks out of the nursery and heads for the gallery
Meet the ‘Endies’ – city dwellers who are too poor to have fun

Meet the ‘Endies’ – city dwellers who are too poor to have fun

Urbanites are cursed with an acronym pointing to Employed but No Disposable Income or Savings
Paisley’s decision to make peace with IRA enemies might remind the Arabs of Sadat

Ian Paisley’s decision to make peace with his IRA enemies

His Save Ulster from Sodomy campaign would surely have been supported by many a Sunni imam